Irofulven (MGI Pharma)

Area of Science:

• Oncology
• Pharmacology
• Natural Product Chemistry

Background:

• Malignant tumors, including ovarian, prostate, hepatocellular, breast, lung, and colon cancers, present significant therapeutic challenges, particularly in refractory and relapsed cases.
• Illudin S, a toxin isolated from the Omphalotus illudens mushroom, has demonstrated cytotoxic properties.
• Irofulven is a semi-synthetic derivative of illudin S, developed to harness its anti-tumor potential.

Purpose of the Study:

• To evaluate the efficacy and safety of irofulven as a potential treatment for refractory and relapsed cancers.
• To explore irofulven's utility as both a monotherapy and in combination regimens.

Main Methods:

• Clinical trials, specifically Phase II, are being conducted to assess irofulven's performance.
• The study involves multiple cancer types, including ovarian, prostate, hepatocellular, breast, lung, and colon cancers.
• Irofulven is administered as a single agent or in combination with other therapeutic agents.

Main Results:

• Ongoing Phase II trials are investigating irofulven's activity in various solid tumors.
• Preliminary data from ongoing trials will inform the compound's therapeutic potential.
• The study aims to establish optimal dosing and combination strategies.

Conclusions:

• Irofulven shows promise as a novel therapeutic agent for difficult-to-treat cancers.
• Further clinical evaluation is necessary to confirm its efficacy and safety profile.
• The development of irofulven represents a potential advancement in the treatment of refractory and relapsed malignancies.